Once- Versus Twice-Weekly Carfilzomib in Relapsed and Refractory Multiple Myeloma by Select Patient Characteristics: Phase 3 A.R.R.O.W. Study Subgroup Analysis
Blood Cancer Journal - United States
doi 10.1038/s41408-020-0300-y
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2020
Authors
Publisher
Springer Science and Business Media LLC